It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651).
The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized Phase 3 Studies‘ was presented at the AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
Questions
- Could you give us a brief overview of the design of the TRuE-AD1 and TRuE-AD2 studies? (0:19)
- What did these studies teach us about the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis? (1:03)
- What was the objective of the analysis you are presenting? (2:59)
- How well were the objectives met and what is the clinical significance of these findings? (4:28)
- Which patients are most likely to respond well to treatment with ruxolitinib cream? (7:58)
Disclosures: KAP has served as a consultant, speaker, clinical researcher, scientific officer, steering committee member, or advisor for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dice Pharmacueticals, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck- Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, UCB and Xencor.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the AAD VMX 2021.
